INTANGIBLE ASSETS, NET	6 Months Ended
Jun. 30, 2022
INTANGIBLE ASSETS, NET
INTANGIBLE ASSETS, NET	NOTE 7—INTANGIBLE ASSETS, NET The Company’s intangible assets, net as of June 30, 2022 totaled $1,574,000 and related to capitalized milestone payments accrued following FDA approval and commercialization of DANYELZA. The intangible assets net book value as of June 30, 2022 is net of $226,000 of accumulated amortization. The Company’s intangible assets, net as of December 31, 2021 totaled $1,663,000. The intangible assets net book value as of December 31, 2021 is net of $137,000 of accumulated amortization. Intangible assets are amortized on a straight-line basis based on a 10-year useful life of the assets. Annual amortization expense is expected to be $180,000 each year for the five-year period from 2022 to 2026.

INTANGIBLE ASSETS, NET

6 Months Ended

Jun. 30, 2022

NOTE 7—INTANGIBLE ASSETS, NET

The Company’s intangible assets, net as of June 30, 2022 totaled $1,574,000 and related to capitalized milestone payments accrued following FDA approval and commercialization of DANYELZA. The intangible assets net book value as of June 30, 2022 is net of $226,000 of accumulated amortization.

The Company’s intangible assets, net as of December 31, 2021 totaled $1,663,000. The intangible assets net book value as of December 31, 2021 is net of $137,000 of accumulated amortization.

Intangible assets are amortized on a straight-line basis based on a 10-year useful life of the assets. Annual amortization expense is expected to be $180,000 each year for the five-year period from 2022 to 2026.